ea0063p570 | Diabetes, Obesity and Metabolism 2 | ECE2019
Ackermann Daniel
, Jamin Heidi
, Klossner Rahel
, Dick Bernhard
, Mohaupt Markus
, Gennari-Moser Carine
Background: Despite normal aldosterone levels, diabetics often profit from the treatment with mineralocorticoid receptor (MR) antagonists (MRAs). We therefore speculated if the expression of MR and 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) were changed in cells of glomerular origin under diabetic conditions and if not - whether the synthesis of other corticosteroid hormones, that could act on MR, was increased in diabetics.Metho...